Andrew Aromando
CIK 1976455 · Chief Business Officer · last filed 2026-06-03
Andrew Aromando is a Chief Business Officer who has filed 6 SEC Form 4 insider transactions across 2 companies since 2023. The most recent filing, for ONCY, was dated Jun 3, 2026. Across all open-market trades the lifetime net is +$25.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $44.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$44.2K
2
6
$25.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONCY | Chief Business Officer | 55,100 | $0.80 | $44.2K | $25.4K | 2 | 2026-06-03 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | Chief Operating Officer | 109,263 | $28.00 | $3.06M | $0 | 4 | 2024-03-07 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | ONCY | Grant (A) | — | $0 | EDGAR |
| 2026-02-13 | ONCY | Buy (P) | +29,600 | $25.4K | EDGAR |
| 2024-03-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-12-11 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +100,000 | $0 | EDGAR |
| 2023-07-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-05 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | — | $0 | EDGAR |